In critically ill sepsis patients on broad-spectrum antibiotics, taking probiotics for one week does not restore gut microbial diversity or reduce harmful bacteria, and these patients continue to have high levels of Enterobacteriaceae.
See the scientific wording
In critically ill sepsis patients receiving broad-spectrum antibiotics, a one-week course of probiotics containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis at a dosage of 8 capsules daily does not restore gut microbial diversity or suppress pathogenic taxa and is associated with continued dominance of Enterobacteriaceae.
Very strong evidence
Randomized trialsOne good-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman2026
In very sick septic patients on strong antibiotics, taking a common probiotic pill for a week didn’t fix their gut bacteria or reduce harmful bugs — the bad bacteria like Enterobacteriaceae kept dominating, just like the claim says.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Antibiotics kill off most gut bacteria, including helpful ones, leaving space for tough, resistant bacteria to take over. When probiotics are given, they cannot grow or stick around because the antibiotics keep killing them. Without enough good bacteria to compete, the resistant bacteria multiply and stay in control, so the gut stays unhealthy.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In critically ill sepsis patients on broad-spectrum antibiotics, taking probiotics for one week does not restore gut microbial diversity or reduce harmful bacteria, and these patients continue to have high levels of Enterobacteriaceae.
Mechanism
1 studyAntibiotics kill off most gut bacteria, including the helpful ones. The probiotics given can't survive or grow because the antibiotics keep killing them. Without enough good bacteria to compete, the harmful ones take over and stay in control.
Antibiotics kill off most gut bacteria, including helpful ones, leaving space for tough, resistant bacteria to take over. When probiotics are given, they cannot grow or stick around because the antibiotics keep killing them. Without enough good bacteria to compete, the resistant bacteria multiply and stay in control, so the gut stays unhealthy.
Broad-spectrum antibiotics eliminate a wide range of commensal gut bacteria, disrupting microbial niches and reducing metabolic resources available for colonization
Orally administered probiotic strains are introduced into the antibiotic-exposed gut lumen but are suppressed by ongoing antibiotic pressure, preventing stable colonization
Failure of probiotic engraftment results in no restoration of microbial diversity or functional metabolic pathways
Loss of colonization resistance allows antibiotic-resistant opportunistic pathogens, particularly Enterobacteriaceae, to expand and dominate the gut ecosystem
The gut microbiome remains in a state of dysbiosis characterized by low diversity and persistent pathogen dominance
Evidence from Studies
Supporting (1)
Community contributions welcome
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial
In very sick septic patients on strong antibiotics, taking a common probiotic pill for a week didn’t fix their gut bacteria or reduce harmful bugs — the bad bacteria like Enterobacteriaceae kept dominating, just like the claim says.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Probiotic Effects on Gut Microbiota in Critically Ill Sepsis Patients on Broad-Spectrum Antibiotics
Population: Critically ill sepsis patients on broad-spectrum antibiotics; Intervention: Probiotics (Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis, 8 capsules daily); Comparator: Placebo or no probiotics; Outcome: Gut microbial diversity (alpha/beta diversity metrics), relative abundance of pathogenic taxa, Enterobacteriaceae dominance; Duration: One week.
Double-Blind, Placebo-Controlled Trial of Probiotics on Gut Microbiota in Critically Ill Sepsis Patients
Population: Critically ill sepsis patients on broad-spectrum antibiotics; Intervention: Probiotics (Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis, 8 capsules daily); Comparator: Placebo capsules; Outcome: Gut microbial diversity (shotgun metagenomics), pathogenic taxa abundance, Enterobacteriaceae relative abundance; Duration: One week; Design: Randomized, double-blind, stratified by severity.
Prospective Cohort Study of Probiotic Use and Gut Microbiota Dynamics in Critically Ill Sepsis Patients
Population: Critically ill sepsis patients on broad-spectrum antibiotics; Exposure: Probiotic use (8 capsules daily for one week); Comparator: Non-probiotic users; Outcome: Gut microbial diversity, pathogenic taxa abundance, Enterobacteriaceae dominance measured at baseline and day 7; Duration: One week; Design: Prospective, longitudinal, adjusted for confounders (antibiotic type, ICU stay, comorbidities).
Cross-Sectional Analysis of Gut Microbiota in Critically Ill Sepsis Patients Receiving Probiotics vs. No Probiotics
Population: Critically ill sepsis patients on broad-spectrum antibiotics; Exposure: Probiotic use (8 capsules daily for one week); Comparator: No probiotic use; Outcome: Gut microbial diversity and Enterobacteriaceae abundance measured at end of week; Duration: Single time point; Design: Retrospective or concurrent sampling without temporal sequence.
In Vitro Assessment of Probiotic Strains on Enterobacteriaceae Growth and Microbial Community Structure in Simulated Gut Media
Population: Pure cultures of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis and Enterobacteriaceae; Intervention: Co-culture with probiotics at concentrations mimicking 8 capsules daily; Comparator: Enterobacteriaceae alone; Outcome: Growth kinetics, relative abundance shifts, metabolite profiles; Duration: 24–72 hours; Design: Controlled laboratory environment with defined media.